Answers are grounded in this paper and cite their sources.
Objective: To analyze the effect of Danshen polyphenols combined with doxofylline treatment in patients with chronic pulmonary heart disease in the compensated stage. Methods: 76 patients with chronic pulmonary heart disease in the compensated stage were selected from January 2023 to January 2024 as the study subjects, and they were divided into a study group and a reference group through a random number table. the study group was treated with Danshen polyphenols combined with doxorubicin while the reference group was treated with conventional treatment, and the treatment effects of the two groups were compared. Results: The patients in the study group were treated with Danshen polyphenols combined with doxorubicin, and the maximal ventilation was 73.26 ± 4.83 L/min, the left ventricular ejection fraction was 56.14 ± 1.98 %, and the total effective rate of the treatment was 94.74%, which were all significantly better than those of the reference group (P < 0.05), which is statistically significant. Conclusion: Danshen polyphenols combined with doxofylline treatment resulted in an improvement in maximum ventilation and left ventricular ejection fraction, and its overall efficacy is also higher than conventional treatment in treating chronic pulmonary heart disease in the compensated stage.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: